Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells.
Acquisition of platinum resistance following first line platinum/taxane therapy is commonly observed in ovarian cancer patients and prevents clinical effectiveness. There are few options to prevent platinum resistance; however, demethylating agents have been shown to resensitize patients to platinum...
Main Authors: | Michaela L Granados, Laurie G Hudson, Sabrina L Samudio-Ruiz |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4564275?pdf=render |
Similar Items
-
The Epidermal Growth Factor Receptor Responsive miR-125a Represses Mesenchymal Morphology in Ovarian Cancer Cells
by: Karen D. Cowden Dahl, et al.
Published: (2009-11-01) -
Common biological phenotypes characterize the acquisition of platinum-resistance in epithelial ovarian cancer cells
by: Maura Sonego, et al.
Published: (2017-08-01) -
Roles of epidermal growth factor receptor and its ligands in ovarian cancer
by: Xin, Qiu
Published: (2015) -
Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma by Targeting the Epidermal Growth Factor Receptor Combined with Gemcitabine Plus Platinum
by: Chen C, et al.
Published: (2020-10-01) -
Human epidermal growth factor receptor targeted inhibitors for the treatment of ovarian cancer
by: Maria Bonello, et al.
Published: (2018-12-01)